Cel-Sci cancer news

Cel-Sci hired BroadOak Capital Partners to outsource its excess manufacturing capabilities and identify license or joint venture opportunities to support the Phase III trial of Multikine. Cel-Sci will delay the start of a Phase III trial of the combination of cytokines to treat head and neck cancer until it secures sufficient funds. Cel-Sci's marketing partners Orient Europharma Co. Ltd. (Taipei, Taiwan) and Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA, Jerusalem, Israel) will fund a portion of the trial. Orient has rights to Multikine in the Asia-Pacific region and Teva has rights in Israel and Turkey. Cel-Sci also obtained a $5 million line of credit from an undisclosed source (see BioCentury, Nov. 10, 2008). ...